DEO vs BUD vs STZ vs BEAM vs TAP

For growth investors, Beam Therapeutics Inc.

(BEAM) is the stronger pick with 120. 0% revenue growth year-over-year, versus -4. 2% for Molson Coors Beverage Company (TAP). Diageo plc (DEO) offers the better valuation at 19. 7x trailing P/E (17. 8x forward), making it the more compelling value choice. Analysts rate Anheuser-Busch InBev SA/NV (BUD) a "Buy" — based on 45 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Diageo plc (DEO) is the cheapest at 19.

7x versus Anheuser-Busch InBev SA/NV at 28. 1x. On forward P/E, Molson Coors Beverage Company is actually cheaper at 9. 2x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Anheuser-Busch InBev SA/NV (BUD) delivered a total return of +12.

4%, compared to -55. 6% for Beam Therapeutics Inc. (BEAM). Over 10 years, the gap is even starker: BEAM returned +67. 8% versus TAP's -41. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Molson Coors Beverage Company (TAP) is the lower-risk stock at -0.

01β versus Beam Therapeutics Inc. 's 2. 14β — meaning BEAM is approximately -17801% more volatile than TAP relative to the S&P 500. On balance sheet safety, Beam Therapeutics Inc. (BEAM) carries a lower debt/equity ratio of 24% versus 185% for Diageo plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Beam Therapeutics Inc.

(BEAM) is pulling ahead at 120. 0% versus -4. 2% for Molson Coors Beverage Company (TAP). On earnings-per-share growth, the picture is similar: Beam Therapeutics Inc. grew EPS 82. 3% year-over-year, compared to -302. 8% for Molson Coors Beverage Company. Over a 3-year CAGR, BEAM leads at 31. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Diageo plc (DEO) is the more profitable company, earning 11.

6% net margin versus -57. 2% for Beam Therapeutics Inc. — meaning it keeps 11. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: STZ leads at 35. 5% versus -274. 6% for BEAM. At the gross margin level — before operating expenses — BEAM leads at 84. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Molson Coors Beverage Company (TAP) trades at 9.

2x forward P/E versus 18. 8x for Anheuser-Busch InBev SA/NV — 9. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DEO: 48. 6% to $124. 00.

In this comparison, DEO (4.

9% yield), TAP (4. 5% yield), STZ (2. 7% yield), BUD (1. 6% yield) pay a dividend. BEAM does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Molson Coors Beverage Company (TAP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

01), 4. 5% yield). Beam Therapeutics Inc. (BEAM) carries a higher beta of 2. 14 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TAP: -41. 4%, BEAM: +67. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (DEO (Consumer Defensive) and BUD (Consumer Defensive) and STZ (Consumer Defensive) and BEAM (Healthcare) and TAP (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: DEO is a mid-cap income-oriented stock; BUD is a mid-cap quality compounder stock; STZ is a mid-cap quality compounder stock; BEAM is a small-cap high-growth stock; TAP is a small-cap income-oriented stock. DEO, BUD, STZ, TAP pay a dividend while BEAM does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.